Early Onset Neutropenia due to Rituximab Therapy in Mantle Cell Lymphoma: A Case Report

Blessie Elizabeth Nelson; Shelby Tipton; Rohit Venkatesan

doi:10.14740/jh814

Early Onset Neutropenia due to Rituximab Therapy in Mantle Cell Lymphoma: A Case Report

J Hematol. 2021 Jun;10(3):136-138. doi: 10.14740/jh814. Epub 2021 Jun 16.

Authors

Blessie Elizabeth Nelson¹, Shelby Tipton², Rohit Venkatesan³

Affiliations

¹ Department of Hematology & Oncology, University of Texas Medical Branch, Galveston, TX, USA.
² Department of Internal Medicine, University of Texas Medical Branch, Galveston, TX, USA.
³ Department of Hematology & Oncology, MD Anderson Cancer Center, Houston, TX, USA.

PMID: 34267851
PMCID: PMC8256914
DOI: 10.14740/jh814

Abstract

Cases of late onset neutropenia (LON) after rituximab therapy have been documented, but few cases have been documented of early onset neutropenia (EON). We present a case report of a patient with mantle cell lymphoma who presented with EON, only 6 days after initiation of rituximab therapy, notable for the shortest duration to EON ever reported in literature. Throughout this paper, we explore the potential pathogenesis and incidence of EON with the help of our unique case.

Keywords: Lymphoma; Neutropenia; Rituximab.

Publication types

Case Reports